Biotech updates 09/13: $ACOR Inbrija PDUFA 1/5 (3 mth ext) $AZN Lumoxiti FDA Approval $ARDX Tenapanor NDA filing $REGN EYLEA Diabetic Retinopathy PDUFA 5/13 $ATOS $INCY $PTN $VRNA $VTGN pipeline updates https://www.biopharmcatalyst.com/news/2018/acorda-a

20:31 EDT 13 Sep 2018 | Odi Bruckman

Biotech updates 09/13: $ACOR Inbrija PDUFA 1/5 (3 mth ext) $AZN Lumoxiti FDA Approval $ARDX Tenapanor NDA filing $REGN EYLEA Diabetic Retinopathy PDUFA 5/13 $ATOS $INCY $PTN $VRNA $VTGN pipeline updates https://www.biopharmcatalyst.com/news/2018/acorda-acor-inbrija-pdufa-date-extended-three-months-astrazeneca-azn-lumoxiti-fda-approval …

More From BioPortfolio on "Biotech updates 09/13: $ACOR Inbrija PDUFA 1/5 (3 mth ext) $AZN Lumoxiti FDA Approval $ARDX Tenapanor NDA filing $REGN EYLEA Diabetic Retinopathy PDUFA 5/13 $ATOS $INCY $PTN $VRNA $VTGN pipeline updates https://www.biopharmcatalyst.com/news/2018/acorda-a"